Article Text

Download PDFPDF
4CPS-094 Improving chronic hepatitis b virus outcomes using a web and smartphone-based medication self-management platform
  1. M Mensa,
  2. P Amorós,
  3. H Anglada,
  4. C Chaguaceda,
  5. JM Sotoca,
  6. M Martin,
  7. C Codina
  1. Hospital Clínic, Pharmacy, Barcelona, Spain


Background Adherence to medication is a major problem in chronic diseases. Mobile health applications can be used as a support tool and could enhance the empowerment of patients with chronic illness.

Purpose Our aim is to assess a medication self-management platform, Medplan, in order to improve adherence and health outcomes in chronic hepatitis B virus (HBV)-infected patients.

Material and methods A 6 month single-arm prospective pre-post intervention study was performed. Patients receiving treatment for chronic HBV infection were included. Participants were followed according to their usual care in the pre-intervention phase, and after 3 months, using Medplan (intervention phase). Medplan reminds patients to take their medications, provides drug information, is a patient-healthcare professionals communication channel and provides an adherence registration tool. Adherence and quality of life were determined using validated tools (simplified medication adherence questionnaire (SMAQ), proportion of days covered with medication (PDC) and EuroQol-5 Dimension (EQ-5D) questionnaire). HBV DNA pre- and post-intervention was collected. Medplan;s usefulness and patients’ self-registered adherence were analysed. The study was approved by the ethics committee. Informed consent was required.

Results Of the 82 patients enrolled, 36 patients (43.9%) withdrew from the study, for the following reasons: difficulties installing and using Medplan (n=9), technical issues (application does not work/reminders did not trigger, n=7) and unwillingness to use the application (n=4). Nine patients are still in the study. Study population comprises 37 patients (73% males, 54±10 years, one naïve patient). The number of adherent patients increased during intervention: 20/37 to 26/36 by SMAQ (1one patient did not answer the final questionnaire) and 95.7±12.4 to 98.7%±5 by PDC. No changes were found in the mean quality of life during the study. The number of patients with undetectable HBV DNA increased using Medplan, from 17 at the beginning to 26 at the end of the study (three results are pending). Medplan application registered adherence was 91.6%±13%. Mean utility score was 8.4 out of 10 among patients.

Conclusion Medplan platform could improve medication adherence and health outcomes for chronic HBV patients. Technical problems must be solved in order to include more patients. Further studies are required.

Reference and/or Acknowledgements 1. Anglada H, et al. J Med Syst2017;41(8):122.

No conflict of interest

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.